Supporting data for BISMUTH-BASED DRUGS AND AGENTS AS ANTI-SARS-COV-2 AGENTS AND NEPHROTOXICITY SCAVENGERS

Metal compounds have long been used in clinic for the treatment and diagnosis of various diseases (e.g., platinum-based anti-cancer drugs, bismuth-based anti-ulcer drugs and gadolinium-based MRI imaging) and have enormous potential for emerging infectious diseases. For example, COVID-19 pandemic unprecedently triggers global public health issue while effective treatment options remain limited. Collectively, these findings validate the potential to expedite the development of bismuth (III) based agents and provide novel insights into the molecular basis of metallodrugs and stimulate translational research to flourish.